IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Roche agrees to acquire biotech firm Seragon Pharmaceuticals

1:22 AM MDT | July 2, 2014 | Natasha Alperowicz

Pharma major Roche (Basel) announced today that its Genentech subsidiary has entered into a definitive agreement to acquire Seragon Pharmaceuticals (San Diego), a privately held biotechnology company. Genentech, through the acquisition, obtains rights to Seragon’s entire portfolio of investigational, next-generation, oral selective estrogen receptor degraders (SERDs) for potentially treating hormone-receptor-positive breast cancer. Under the terms of the agreement, Genentech will make an upfront cash payment of $725 million plus additional contingent...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa